Journal of Psoriasis and Psoriatic Arthritis最新文献

{"title":"Safety of IL-17A Inhibitors in Patients With Moderate to Severe Psoriasis in a US Claims Data-Based Cohort Study.","authors":"Maria C Schneeweiss, Joseph F Merola, Yinzhu Jin, Richard Wyss, Priyanka Anand, Arash Mostaghimi, Sebastian Schneeweiss, Robert J Glynn","doi":"10.1177/24755303261446193","DOIUrl":"https://doi.org/10.1177/24755303261446193","url":null,"abstract":"<p><strong>Background: </strong>Safety outcomes from IL-17A inhibitors have not been fully evaluated.</p><p><strong>Objective: </strong>Compare the risk of seven safety outcomes in patients with psoriasis who started treatment with either ixekizumab or secukinumab vs other biologics to treat psoriasis.</p><p><strong>Methods: </strong>In this cohort study (Apr 2016 - Dec 2022), we used US claims data to assess the risk of infections, major adverse cardiac events (MACE), inflammatory bowel disease (IBD), malignancy, and anaphylaxis, in patients with psoriasis starting an IL-17A inhibitor vs other biologics (TNF, IL-12/23, or IL-23 inhibitors).</p><p><strong>Results: </strong>Among 4261 IL-17A inhibitors users we observed no meaningfully increased risk of MACE (RR = 0.67, 0.27-1.63), or malignancy (RR = 0.92, 0.58-1.45) vs patients initiating other biologics. After propensity score matching IL-17A inhibitors users had a 3-fold increase in the risk of oral candidiasis (RR = 3.43; 1.48-7.84), a 19% increase in the risk of outpatient infections (RR = 1.19; 1.05-1.35) and a 40% increased risk of serious infections with wide confidence intervals (RR = 1.40; 0.72-2.71). We observed a signal for an increased risk of IBD based on very few events.</p><p><strong>Conclusion: </strong>Patients with psoriasis using an IL-17A inhibitor had an increased risk of oral candidiasis and outpatient infections but no increase for MACE, anaphylaxis, or malignancy compared to other biologics.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261446193"},"PeriodicalIF":0.0,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sociodemographic Factors Associated With Diagnosed Psoriasis in U.S. Adults: Patterns and Trends From NHANES and NHIS, 2003-2024.","authors":"Moshe Schneiderman, Kristina M Derrick","doi":"10.1177/24755303261448484","DOIUrl":"https://doi.org/10.1177/24755303261448484","url":null,"abstract":"<p><strong>Objective: </strong>To quantify sociodemographic differences in the prevalence of diagnosed psoriasis and to evaluate temporal trends in its epidemiologic distribution.</p><p><strong>Methods: </strong>Data from the 2003-2006 and 2009-2014 National Health and Nutrition Examination Survey and the 2023-2024 National Health Interview Survey were analyzed. Meta-analysis was performed to determine whether age, sex, race/ethnicity, interview language, marital status, BMI, education, income, and health insurance are independently associated with odds of diagnosed psoriasis. Estimates from each survey period were tested for linear trends over time.</p><p><strong>Results: </strong>The total sample included 53,225 participants. Spanish speakers, compared to English speakers, demonstrated markedly lower prevalence of diagnosed psoriasis (pooled aOR = 0.40, 95% CI = 0.25-0.65), even after adjusting for other sociodemographic factors including race/ethnicity. Other factors independently associated with psoriasis were older age, non-Hispanic White race/ethnicity, and higher BMI (all <i>P</i> < 0.001). No temporal trends in prevalence were found in any sociodemographic subgroup.</p><p><strong>Conclusion: </strong>This analysis of national data covering an almost 25-year period indicates psoriasis has consistently been one of the most common inflammatory skin diseases with a stable sociodemographic distribution over this time. High rates of potentially undiagnosed psoriasis among vulnerable sociodemographic subgroups may be a persistent issue spanning over 2 decades. Patients with limited English proficiency may have difficulty interacting with the healthcare system, leading to undiagnosed psoriasis. Difficulty of diagnosis in patients with skin of color may also contribute. Given that psoriasis is a condition with systemic effects, including impacts on cardiovascular risk, accurate and timely diagnosis is essential to ensure appropriate clinical management.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261448484"},"PeriodicalIF":0.0,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13135622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ambient Temperature and Psoriatic Arthritis Odds Among Patients With Psoriasis: A Cross-sectional Analysis.","authors":"Michael R Nock, Stacy Ahn, Charles E Leonard, Alexis Ogdie, Jeffrey M Cohen","doi":"10.1177/24755303261446203","DOIUrl":"https://doi.org/10.1177/24755303261446203","url":null,"abstract":"<p><strong>Background: </strong>Although there has been growing interest in better understanding risk factors for progression from psoriasis (PsO) to psoriatic arthritis (PsA), research on the role of ambient temperature in potentiating PsA risk has been limited. We sought to evaluate the association of average-annual ambient temperature exposure with prevalent PsA diagnosis among a large cohort of US adults with PsO.</p><p><strong>Methods: </strong>We studied electronic health record-data from participants with PsO, with and without an associated PsA diagnosis, who enrolled in the National Institutes of Health's All of Us Research Program between May 31, 2017, and July 1, 2022. Average-annual ambient temperature exposure data was obtained from the National Oceanic and Atmospheric Administration. Multivariable logistic regression analysis was utilized to assess the association between three-digit Zone Improvement Plan (ZIP) code-level ambient temperatures and prevalent PsA diagnosis, controlling for patient age, sex, body mass index, smoking history, race and ethnicity, income, urbanicity, and community deprivation.</p><p><strong>Results: </strong>In this cohort of 5466 patients with PsO (mean age [SD], 61.86 years [15.45 years]; 3153 females [57.7%]) and 1080 patients with both PsO and PsA (mean age [SD], 60.76 years [13.48 years]; 665 females [61.6%]), each 1°F increase in average-annual ambient temperature was associated with 2% increased odds of prevalent PsA diagnosis (adjusted odds ratio [aOR], 1.02; 95% CI, 1.01-1.03).</p><p><strong>Conclusion: </strong>Our study provides data to support further investigation of long-term, warmer ambient temperature exposure as a potential risk factor for PsA among those with PsO.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261446203"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Arthritis in a Large Real-World Cohort of Patients With Pediatric Onset Psoriasis.","authors":"Malak Al-Gawahiri, Elke M G J de Jong, Ellen J H Schatorjé, Esther P A H Hoppenreijs, Juul M P A van den Reek, Marieke M B Seyger","doi":"10.1177/24755303261446205","DOIUrl":"https://doi.org/10.1177/24755303261446205","url":null,"abstract":"<p><strong>Background: </strong>Early identification and treatment of psoriatic arthritis (PsA) among patients with psoriasis is important to prevent joint damage. Insights in arthritis onset and the associated clinical factors among pediatric and young adult patients with psoriasis is scarce.</p><p><strong>Objectives: </strong>To describe pediatric patients with psoriasis who subsequently developed psoriatic arthritis at pediatric age or in young adulthood (JPsA/PsA). We focused on clinical features and timing of onset, and compared clinical features to characteristics of a large cohort of pediatric psoriasis patients.</p><p><strong>Methods: </strong>Data on patients with pediatric onset of psoriasis were obtained from the prospective, daily practice, ChildCAPTURE registry. Descriptive statistics were used. ILAR and CASPAR criteria were used for classification of JPsA and PsA, respectively. The time to JPsA/PsA diagnosis following psoriasis onset was analyzed using Kaplan-Meier survival analysis.</p><p><strong>Results: </strong>Among 717 pediatric and young adult patients with psoriasis, 15 (2.1%) developed arthritis, of which 8 patients before the age of 18 years (1.1%, JPsA) and 7 patients in young adulthood (1.0%, PsA), with an estimated incidence of 2.8% within 10 years after psoriasis diagnosis. The median interval between psoriasis onset and JPsA/PsA development was 4.8 years. Male sex, obesity, and nail involvement were common clinical features of patients developing JPsA/PsA, and these were observed more frequently compared to the total pediatric psoriasis cohort.</p><p><strong>Conclusion: </strong>The incidence of JPsA/PsA among patients with pediatric onset of psoriasis is low. If the clinical features male sex, obesity and nail involvement are present, extra awareness for the development of JPsA/PsA is warranted.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261446205"},"PeriodicalIF":0.0,"publicationDate":"2026-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110248/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical Enthesitis in Psoriasis Patients as Predictors of Arthritis: The EPESCA Study.","authors":"Eleonora Di Donato, Andrea Becciolini, Sergio Di Nuzzo, Nataliya Chernyschova, Claudio Commisso, Sveva Lamorte, Carolina Fantini, Francesca Satolli, Daniele Santilli, Gianluca Lucchini, Claudio Feliciani, Nicola Sverzellati, Alarico Ariani","doi":"10.1177/24755303261446216","DOIUrl":"https://doi.org/10.1177/24755303261446216","url":null,"abstract":"<p><p><b>Background:</b> Enthesitis, a key feature of psoriatic arthritis (PsA), can be detected subclinically by ultrasound (US) in patients with psoriasis (PsO), where it may signal an increased risk of future articular involvement. <b>Purpose:</b> This observational study aimed to investigate the prevalence of subclinical enthesitis in PsO patients without musculoskeletal symptoms, analyze the differences between patients with enthesis alterations (i.e. active enthesitis - AE, inactive enthesitis - En, enthesopathy - Ep or none - wE, per OMERACT criteria) and evaluate the 1 year PsA incidence. <b>Research design:</b> All consecutive PsO patients ≥18 years attending a dermatology outpatient clinic were screened. A rheumatologist and a radiologist experienced in US performed greyscale and Power Doppler (PD) examination on six bilateral enthesal sites (Achilles, quadriceps, distal/proximal patellar, plantar fascia, and triceps enthesis). The chi-square test or Kruskall-Wallis test detected the differences between the groups. After 1 year, rheumatologists reassessed En and AE patients for PsA onset. A <i>P</i>-value ≤0.05 was considered statistically significant. <b>Results:</b> Among 211 enrolled subjects, AE, En, and Ep prevalences were 6.6%, 35.6%, and 31.8%, respectively. There were no alterations in 23.2% while 2.8% showed only PD signal. BMI was higher in En than in wE and Ep (28, 24 and 25 kg/m^2 respectively) (<i>P</i> < 0.05). Female were less prevalent in En than in Ep (52% vs 25%, <i>P</i> < 0.01). None developed PsA during the 1-year follow-up. <b>Conclusion:</b> Subclinical enthesitis is common in PsO patients (about 40%), with inactive enthesitis more frequent in higher-BMI individuals. Active enthesitis was rare (<7%), and no cases progressed to PsA.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261446216"},"PeriodicalIF":0.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13095994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147783885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter From the New Editor-in-Chief.","authors":"George Han","doi":"10.1177/24755303261432372","DOIUrl":"10.1177/24755303261432372","url":null,"abstract":"","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261432372"},"PeriodicalIF":0.0,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12971499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of Quality of Life and Mental Health in Kenyan Psoriasis Patients: A Cross-Sectional Analysis from the Kenyan Psoriasis Registry.","authors":"Miranda K Chen, Petronilla Biwott, Isabel Muraguri, Georgia Marquez-Grap, Gian Carlo Baldonado, Payton Smith, Toby Maurer, Tina Bhutani, Samson Kiprono, Wilson Liao","doi":"10.1177/24755303261433913","DOIUrl":"https://doi.org/10.1177/24755303261433913","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis is a chronic immune-mediated disease with global prevalence of 2-3% that is associated with significantly reduced quality of life (QoL) and worsened mental health. Despite this, there is a lack of research in African psoriasis populations, with no modern epidemiological studies conducted in Kenya to examine these factors. This study aims to identify demographic and clinical features associated with dermatology-related QoL and mental health among psoriasis patients enrolled in the newly established Kenyan Psoriasis Registry (KPR), based at Moi Teaching and Referral Hospital in Eldoret, Kenya.</p><p><strong>Patients and methods: </strong>In a cross-sectional analysis of 97 adult psoriasis patients enrolled in the KPR, we evaluated associations of demographic and disease characteristics with independent outcomes of dermatology-associated QoL (Dermatology Life Quality Index, DLQI), anxiety (Generalized Anxiety Disorder 7-item, GAD-7), and depression (Patient Health Questionnaire 9-item, PHQ-9). Univariate and multivariate linear regression models were used to identify associations, with <i>P</i> < 0.05 considered statistically significant.</p><p><strong>Results: </strong>In univariate analyses, age, female gender, marital status, certain subethnicities, high-impact body sites, itch and pain, sleep disturbance, and disease severity were factors associated with worse QoL, anxiety, and depression scores. In multivariate analyses, younger age, Itch Numeric Rating Scale, and Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance T-score remained significantly associated with worse DLQI. Both PROMIS Sleep Disturbance and separated marital status were associated with worse GAD-7 and PHQ-9.</p><p><strong>Conclusion: </strong>Kenyan psoriasis patients experience significant QoL and mental health burden, with younger age, itch, sleep disturbance, and separated marital status associated with worse outcomes.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303261433913"},"PeriodicalIF":0.0,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12971513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in Bimekizumab Treated Psoriasis Patients With Prior IL-17 Inhibitor Failure.","authors":"Eingun James Song, Prieuer Pretorius, Diego Ruiz Dasilva, Christopher G Bunick, Clive Liu, Mona Shahriari","doi":"10.1177/24755303251412379","DOIUrl":"10.1177/24755303251412379","url":null,"abstract":"<p><p>Despite advancements in psoriasis therapeutics, biologic discontinuation and switching still happen frequently, with the most common reasons being lack of efficacy or treatment intolerance. Conventional teaching has been to switch out of the class (inter-class switching) for primary non-responders and to stay in the class (intra-class switching) for secondary non-responders. Previous real-world studies have reported success with intra-class switching within the IL-17 inhibitor class, but data have been limited to secukinumab, ixekizumab, and brodalumab. Using retrospective data from cases selected for moderate-to-severe psoriasis who failed prior IL-17 therapy, we report our real-world experience using bimekizumab in 50 patients who failed a prior IL-17 inhibitor, in which 82% achieved an IGA 0/1. By demonstrating achievement of stringent benchmarks, such as IGA 0/1 and sPGAxBSA 100 in these selected patients, we challenge the conventional teaching of primary vs secondary non-responders class switching, and have found bimekizumab to be a viable option in those who have failed IL-17 inhibitor therapy in the past.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251412379"},"PeriodicalIF":0.0,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12783026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriatic Arthritis Characteristics and Comorbidities in North Africa: Results of a Multicenter Retrospective Study.","authors":"Abderrahim Majjad, Sofia El Guarti, Hamza Mansouri, Tarik Youssoufi, Hasna Hassikou, Krystel Efemba, Taoufik Harzy, Safaa Fellous, Fadwa Allali, Soukaina Kabbou, Imad Ghozlani, Abdellah El Maghraoui, Lahcen Achemlal","doi":"10.1177/24755303251412380","DOIUrl":"10.1177/24755303251412380","url":null,"abstract":"<p><strong>Background: </strong>Psoriatic arthritis (PsA) exhibits heterogeneity across different populations. Given the limited research on PsA in Africa, this study aims to characterize disease features and various cardiovascular disease risk factors (CVRFs) in a cohort of patients with PsA.</p><p><strong>Methods: </strong>We enrolled 110 patients fulfilling the CASPAR criteria. PsA. PsA-related parameters and various CVRFs were recorded. Radiographs of hands and feet assessed peripheral joint damages.</p><p><strong>Results: </strong>The study population included 48 males and 62 females, with a mean age of 49.8 ± 12.5 years and a mean disease duration of 9 ± 7 years. The most common disease pattern was polyarthritis, followed by oligoarthritis, spondyloarthritis, and enthesitis. Dactylitis was reported in 33.9% of patients, while 7.6% carried the HLA-B27 gene. Psoriasis was observed in 74.5% of patients, with nail involvement in 30% of cases. Inflammatory bowel disease and uveitis were present in 4.5% and 1.8% of patients, respectively. 77% of patients had active disease. Radiographic joint damage was detected in 47.2% of patients and was significantly associated with disease duration, dactylitis, and biologic therapy use. In this cohort, 23.6% were obese, and 30% were smokers. Comorbidities such as diabetes, hypertension, hyperlipidemia, and gout were present in 22.7%, 19.1%, 29.1%, and 8.1%, respectively. Moreover, 57.3% of patients had two or more CVRFs and 9.1% had a cardiovascular disease.</p><p><strong>Conclusion: </strong>This cohort suggested a female predominance, a lower prevalence of the HLA-B27 gene, a reduced frequency of extra-musculoskeletal manifestations, and a high prevalence of radiographic joint damage and CVRFs.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251412380"},"PeriodicalIF":0.0,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12742996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145850670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Experiences on the Diagnosis, Management, and Burden of Generalized Pustular Psoriasis: An International Web Survey and Qualitative Interview Study.","authors":"Mark Lebwohl, Hideki Fujita, Kilian Eyerich, Andrew E Pink, Min Zheng, Iris Chen-Yin Lai, David Trigos, Anne M Skalicky, Julia R Correll, Ana C Hernandez Daly, Tadashi Terui","doi":"10.1177/24755303251401112","DOIUrl":"10.1177/24755303251401112","url":null,"abstract":"<p><strong>Background: </strong>Generalized pustular psoriasis (GPP) is a rare, serious, chronic, neutrophilic skin disease, distinct from plaque psoriasis, characterized by recurrent flares of cutaneous erythema and widespread sterile pustules. Patient-centric data on the quality of life (QoL) impacts of GPP remain limited.</p><p><strong>Objective: </strong>To evaluate the physical and emotional QoL impacts of GPP.</p><p><strong>Methods: </strong>We used a web-based survey and 90-minute telephone interviews with open-ended questions to evaluate the experiences of adults with GPP across China, Japan, the UK, and the USA. Quantitative measures included the Dermatology Life Quality Index (DLQI), Psoriasis Symptom Scale (PSS), and Worst GPP Pain Numeric Rating Scale (NRS).</p><p><strong>Results: </strong>21 participants completed the survey; 9 completed telephone interviews. The journey to diagnosis was complicated, with 48% of participants seeing ≥4 physicians before the diagnosis. Impacts of GPP on participants physical and mental QoL were substantial, such as the anxiety of not being able to plan life and work with confidence, both in general and during flares. The mean DLQI was 10.2, and the PSS and Worst GPP Pain NRS were highest in participants experiencing recent flares. Participants' biggest worries included risk of flares, distress from symptoms, inadequate treatment, and passing on the disease to their children. Limitations included a small sample size and short recall timeframe.</p><p><strong>Conclusion: </strong>Participants reported multiple impacts of GPP on their daily lives even in the absence of acute flares, highlighting the need for greater disease awareness and understanding among healthcare professionals.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"24755303251401112"},"PeriodicalIF":0.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12657205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}